On the eve of reporting third-quarter earnings, Eli Lilly and Co. confronted a storm warning from Fitch Ratings, which affirmed the big pharma's ratings – including the issuer default rating (IDR) – at "A" but lowered its outlook on the company from "stable" to "negative."